Cyclosporin A has no impact on alterations of the lipid profile after renal transplantation
The literature contains conflicting ideas regarding the role of cyclosporin A (CyA) in the induction of posttransplant dyslipidemia. The available studies contain small numbers of patients, especially on CyA monotherapy. We compared 65 patients on conventional azathioprine-prednisone therapy (AP) with 85 patients on CyA monotherapy, 19 on CyA-azathioprine therapy (CA), 20 on CyA-prednisone therapy (CP), and 52 on a triple therapy with CyA, azathioprine, and prednisone (CAP). From the results, it is concluded that patients on CyA monotherapy had lower serum cholesterol levels, with a lower high-density lipoprotein (HDL)-cholesterol level, probably due to the lower total cholesterol, compared with AP patients. From all groups, the CyA monotherapy group showed the most beneficial lipid profile. No additive negative influences of CyA when combined with other immunosuppressive drugs were noted. Thus, a correlation between derangements of the lipid profile and CyA therapy could not be confirmed. Further analysis of our data showed negative influences of antihypertensive treatment on lipid metabolism, particularly in the case of treatment with β-blockers or diuretics. It cannot be excluded that studies showing a negative influence of CyA therapy on lipid homeostasis were biased by secondary factors like antihypertensive therapy, which was often not taken into account.
Key wordsTransplantation Cyclosporin A Lipids Antihypertensive drugs Insulin sensitivity Immunosuppression
Unable to display preview. Download preview PDF.
- 3.Coronary Drug Project Research Group (1987) Natural history of myocardial infarction in the coronary drug project: long-term prognostic importance of serum lipid levels. Am J Cardiol 42: 489–498Google Scholar
- 6.Fuhrer JA, Horber FF (1990) Additive effects of prednisone and cyclosporine-A therapy on serum cholesterol in renal transplant patients: effect of time interval after kidney transplantation and therapy with fibrates. J Am Soc Nephrol 1:757Google Scholar
- 9.Johnson RWG (1986) Cyclosporine in cadaveric renal transplantation: three-year follow-up of a European multicentre trial. Transplant Proc 18:1229–1233Google Scholar
- 10.Najarian JS (1988) Long term results at the University of Minnesota. Transplant Immunol 4 (4)Google Scholar
- 11.Rosman J, Weidmann P, Ferrari P (1990) Antihypertensive drugs and serum lipoproteins, J Drug Dev 3 [Suppl 1]: 129–139Google Scholar
- 12.Traindl O, Reading S, Franz M, Pohanka E, Pidlich J, Kovarik J (1991) Cyclosporin-A does not cause hyperlipidemia in kidney graft recipients. Clin Transplant 5:265–267Google Scholar